Is it prime time for personalized medicine in cancer treatment?

Personalized Medicine

Volumn 7, Issue 4, 2010, Pages 387-397

  Kho, Patricia S ^a,b   Chua, Wei ^a,b   Moore, Melissa M ^a,b   Clarke, Stephen J ^a,b  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b University of Sydney   (Australia)

Author keywords

Biomarker; Cancer; Chemotherapy; Clinical trial; Personalized medicine; Predictive marker; Prognostic marker; Targeted therapy

Indexed keywords

CETUXIMAB; CYTOCHROME P450 2D6; ERLOTINIB; ESTROGEN RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; IMATINIB; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG METABOLISM; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; LUNG NON SMALL CELL CANCER; ONCOGENE C KIT; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 77956947977     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.32     Document Type: Review

References (94)

1. Ransohoff DF: Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4(4), 309-314 (2004).
2. Henry NL, Hayes DF: Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11(6), 541-552 (2006).
3. Nilsson B, Bmming P, Meis-Kindblom JM et al.: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 103(4), 821-829 (2005).
4. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 33(5), 466-477 (2002).
5. Demetri GD, Von Mehren M, Blanke CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002).
6. Hirota S, Isozaki K, Moriyama Y et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350), 577-580 (1998).
7. Heinrich MC, Corless CL, Duensing A et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607), 708-710 (2003).
8. Heinrich MC, Corless CL, Demetri GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003).
9. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96(3), 925-932 (2000).
10. Blanke CD, Demetri GD, Von Mehren M et al.: Long-term results from a randomized Phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26(4), 620-625 (2008).
11. Heinrich MC, Owzar K, Corless CL et al.: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 26(33), 5360-5367 (2008).
12. Gastrointestinal Stromal Tumor Meta- Analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J. Clin. Oncol. 28(7), 1247-1253 (2010).
13. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22(18), 3813-3825 (2004).
14. Demetri GD, Van Oosterom AT, Garrett CR et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329-1338 (2006).
15. Heinrich MC, Maki RG, Corless CL et al.: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 26(33), 5352-5359 (2008).
16. Judson IR: Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype. J. Clin. Oncol. 26(33), 5322-5325 (2008).
17. Blanke CD: Biomarkers in GIST: partly ready for prime-time use. Clin. Cancer Res. 15(18), 5603-5605 (2009).
18. Goldberg RM, Rothenberg ML, Van Cutsem E et al.: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1), 38-50 (2007).
19. Sanoff HK, Sargent DJ, Campbell ME et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J. Clin. Oncol. 26(35), 5721-5727 (2008).
20. Watine J, Friedberg B: Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin. Chim. Acta 345(1-2), 1-15 (2004).
21. Kohne EA: Clinical determinants of survival in pts with 5-FU based RX for MCRC: results of a MV analysis of 3825 patients. Ann. Oncol. 13, 308-317 (2002).
22. Koopman M, Venderbosch S, Nagtegaal ID, Van Krieken JH, Punt CJ: A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur. J. Cancer 45(11), 1935-1949 (2009).
23. Van Cutsem E, Peeters M, Siena S et al.: Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658-1664 (2007).
24. Lievre A, Bachet J-B, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
25. Bos JL, Fearon ER, Hamilton SR et al.: Prevalence of RAS gene mutations in human colorectal cancers. Nature 327(6120), 293-297 (1987).
26. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: Detection of high incidence of K-RAS oncogenes during human colon tumorigenesis. Nature 327(6120), 298-303 (1987).
27. Tol J, Koopman M, Cats A et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
28. Bokemeyer C, Bondarenko I, Makhson A et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
29. Van Cutsem E, Kohne C-H, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
30. Amado RG, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
31. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
32. Khambata-Ford S, Garrett CR, Meropol NJ et al.: Expression of epiregulin and amphiregulin and k-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007).
33. Di Fiore F, Blanchard F, Charbonnier F et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96(8), 1166-1169 (2007).
34. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al.: Oncogenic activation of the ras/raf signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67(6), 2643-2648 (2007).
35. De Roock W, Piessevaux H, De Schutter J et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 19(3), 508-515 (2008).
36. Allegra CJ, Jessup JM, Somerfield MR et al.: American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
37. Wang HL, Lopategui J, Amin MB, Patterson SD: KRAS mutation testing in human cancers: the pathologists role in the era of personalized medicine. Adv. Anat. Pathol. 17(1), 23-32 (2010).
38. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. 27(7), 1130-1136 (2009).
39. Saif MW, Shah M: K-RAS mutations in colorectal cancer: a practice changing discovery. Clin. Adv. Hematol Oncol. 7(1), 45-53 (2009)
40. Packham D, Ward RL, Ap Lin V, Hawkins NJ, Hitchins MP: Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn. Mol. Pathol. 18(2), 62-71 (2009).
41. Tol J, Dijkstra JR, Vink-Börger ME et al.: High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J. Cell Mol. Med. DOI: 10.1111/j.1582-4934.2009.00788.x (2009) (Epub ahead of print).
42. Frattini M, Saletti P, Romagnani E et al.: Pten loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97(8), 1139-1145
43. Jhawer M, Goel S, Wilson AJ et al.: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. 68(6), 1953-1961 (2008).
44. Sartore-Bianchi A, Martini M, Molinari F et al.: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69(5), 1851-1857 (2009).
45. Bardelli A, Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28(7), 1254-1261 (2010).
46. Yu-Ning W, Neal JM, William S, Daniel S, Richard MG, Beck JR: Cost implications of new treatments for advanced colorectal cancer. Cancer 115(10), 2081-2091 (2009).
47. Mittmann N, Au H-J, Tu D et al.: Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group Co.17 trial. J. Natl Cancer Inst. 101(17), 1182-1192 (2009).
48. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl Cancer Inst. 100(20), 1432-1438 (2008).
49. Ransohoff DF, Gourlay ML: Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol. 28(4), 698-704 (2010).
50. Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for predictive marker validation in cancer treatment trials. 23(9), 2020-2027 (2005).
51. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumour marker prognostic studies (remark). Eur. J. Cancer 41(12), 1690-1696 (2005).
52. Freidlin B, Mcshane LM, Korn EL: Randomized clinical trials with biomarkers: design issues. J. Natl Cancer Inst. 102(3), 152-160 )2010).
53. Burdett S, Stephens R, Stewart L et al.; NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 26(28), 4617-4625 (2008).
54. Herbst RS, Heymach JV, Lippman SM: Lung cancer. N. Engl. J. Med. 359(13), 1367-1380 (2008).
55. Herbst RS, Prager D, Hermann R et al.: TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
56. Herbst RS, Giaccone G, Schiller JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004).
57. Giaccone G, Herbst RS, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
58. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
59. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
60. Tsao M-S, Sakurada A, Cutz J-C et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005).
61. Rosell R, Moran T, Queralt C et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
62. Mok TS, Wu YL, Thongprasert S et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
63. Jackman DM, Miller VA, Cioffredi L-A et al.: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin. Cancer Res. 15(16), 5267-5273 (2009).
64. Cobo M, Isla D, Massuti B et al.: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a Phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 25(19), 2747-2754 (2007).
65. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
66. Sørlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
67. Sørlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
68. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
69. Seshadri R, Firgaira F, Horsfall D, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. Clin. Oncol. 11(10), 1936-1942 (1993).
70. Paik S, Hazan R, Fisher E et al.: Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of ErbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol. 8(1), 103-112 (1990).
71. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
72. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
73. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
74. Wolff AC, Hammond Meh, Schwartz JN et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
75. Shah SS, Ketterling RP, Goetz MP et al.: Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum. Pathol. 41(1), 103-106 (2010).
76. Kiyotani K, Mushiroda T, Imamura CK et al.: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28(8), 1287-1293 (2010).
77. Schroth W, Goetz MP, Hamann U et al.: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
78. Wegman P, Vainikka L, Stal O et al.: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3), R284-R290 (2005).
79. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S: Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10(8), 825-833 (2009).
80. Goetz M, Berry D, Klein T; International Tamoxifen Pharmacogenomics Consortium: Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the international tamoxifen pharmacogenomics consortium. Cancer Res. 69(Suppl.), 33 (2009) (Meeting Abstract).
81. Tan S-H, Lee S-C, Goh B-C, Wong J: Pharmacogenetics in breast cancer therapy. Clin. Cancer Res. 14(24), 8027-8041 (2008).
82. Lash TL, Rosenberg CL: Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J. Clin. Oncol. 28(8), 1273-1275 (2010).
83. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
84. Paik S, Tang G, Shak S et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
85. Simes R John CA: Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J. Natl Cancer Inst. Monogr. 146-152 (2001).
86. Goldstein LJ, Gray R, Badve S et al.: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26(25), 4063-4071 (2008).
87. Oratz R, Paul D, Cohn AL, Sedlacek SM: Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J. Oncol. Pract 3(4), 182-186 (2007).
88. Lo SS, Mumby PB, Norton J et al.: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J. Clin. Oncol. 28(10), 1671-1676 (2010).
89. Sparano JA, Solin LJ: Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making. J. Clin. Oncol. 28(10), 1625-1627 (2010).
90. Lyman GH, Cosler LE, Kuderer NM, Hornberger J: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer. Cancer 109(6), 1011-1018 (2007).
91. Van De Vijver MJ, He YD, Van T Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
92. Cardoso F, Vant Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ: Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26(5), 729-735 (2008).
93. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101(21), 1446-1452 (2009).
94. Hayes DF: Clinical utility of tumor markers: study design and evaluation. Am. Assoc. Cancer Res. Educ. Book 2009(1), 273-277 (2009).